Cargando…
Stimuli‐responsive crosslinked nanomedicine for cancer treatment
Nanomedicines are attractive paradigms to deliver drugs, contrast agents, immunomodulators, and gene editors for cancer therapy and diagnosis. However, the currently developed nanomedicine suffers from poor serum stability, premature drug release, and lack of responsiveness. Crosslinking strategy ca...
Autores principales: | Xue, Xiangdong, Qu, Haijing, Li, Yuanpei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190936/ https://www.ncbi.nlm.nih.gov/pubmed/37324805 http://dx.doi.org/10.1002/EXP.20210134 |
Ejemplares similares
-
Stimuli-responsive prodrug-based cancer nanomedicine
por: Xie, Angel, et al.
Publicado: (2020) -
Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance
por: Zhou, Lei, et al.
Publicado: (2018) -
Stimuli-activatable nanomedicine meets cancer theranostics
por: Li, Haonan, et al.
Publicado: (2023) -
Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
por: Zhao, Yijun, et al.
Publicado: (2021) -
Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy
por: Su, Yuanzhen, et al.
Publicado: (2023)